1
|
Dogan AB, Dabkowski KE, von Recum HA. Leveraging Affinity Interactions to Prolong Drug Delivery of Protein Therapeutics. Pharmaceutics 2022; 14:1088. [PMID: 35631672 PMCID: PMC9144912 DOI: 10.3390/pharmaceutics14051088] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Revised: 05/07/2022] [Accepted: 05/17/2022] [Indexed: 12/10/2022] Open
Abstract
While peptide and protein therapeutics have made tremendous advances in clinical treatments over the past few decades, they have been largely hindered by their ability to be effectively delivered to patients. While bolus parenteral injections have become standard clinical practice, they are insufficient to treat diseases that require sustained, local release of therapeutics. Cyclodextrin-based polymers (pCD) have been utilized as a platform to extend the local delivery of small-molecule hydrophobic drugs by leveraging hydrophobic-driven thermodynamic interactions between pCD and payload to extend its release, which has seen success both in vitro and in vivo. Herein, we proposed the novel synthesis of protein-polymer conjugates that are capped with a "high affinity" adamantane. Using bovine serum albumin as a model protein, and anti-interleukin 10 monoclonal antibodies as a functional example, we outline the synthesis of novel protein-polymer conjugates that, when coupled with cyclodextrin delivery platforms, can maintain a sustained release of up to 65 days without largely sacrificing protein structure/function which has significant clinical applications in local antibody-based treatments for immune diseases, cancers, and diabetes.
Collapse
Affiliation(s)
| | | | - Horst A. von Recum
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, USA; (A.B.D.); (K.E.D.)
| |
Collapse
|
2
|
Agnes M, Pancani E, Malanga M, Fenyvesi E, Manet I. Implementation of Water-Soluble Cyclodextrin-Based Polymers in Biomedical Applications: How Far are we? Macromol Biosci 2022; 22:e2200090. [PMID: 35452159 DOI: 10.1002/mabi.202200090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Revised: 04/06/2022] [Indexed: 11/10/2022]
Abstract
Cyclodextrin-based polymers can be prepared starting from the naturally occurring monomers following green and low-cost procedures. They can be selectively derivatized pre- or post-polymerization allowing to fine-tune functionalities of ad hoc customized polymers. Preparation nowadays has reached the 100 g scale thanks also to the interest of industries in these extremely versatile compounds. During the last 15 years these macromolecules have been the object of intense investigations in view of possible biomedical applications as the ultimate goal and large amounts of scientific data are now available. Compared to their monomeric models, already used in the formulation of various therapeutic agents, they display superior behavior in terms of their solubility in water and solubilizing power towards drugs incompatible with biological fluids. Moreover, they allow the combination of more than one type of therapeutic agent in the polymeric system. In this review we provide a complete state-of-the-art on the knowledge and potentialities of water-soluble cyclodextrin-based polymers as therapeutic agents as well as carrier systems for different types of therapeutics to implement combination therapy. Finally, we give a perspective on their assets for innovation in disease treatment as well as their limits that still need to be addressed. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Marco Agnes
- Istituto per la Sintesi Organica e la Fotoreattività (ISOF), Consiglio Nazionale delle Ricerche (CNR), via P. Gobetti 101, Bologna, 40129, Italy
| | - Elisabetta Pancani
- Advanced Accelerator Applications, A Novartis Company, via Ribes 5, Ivrea, 10010, Italy
| | - Milo Malanga
- CycloLab, Cyclodextrin R&D Ltd., Budapest, H1097, Hungary
| | - Eva Fenyvesi
- CycloLab, Cyclodextrin R&D Ltd., Budapest, H1097, Hungary
| | - Ilse Manet
- Istituto per la Sintesi Organica e la Fotoreattività (ISOF), Consiglio Nazionale delle Ricerche (CNR), via P. Gobetti 101, Bologna, 40129, Italy
| |
Collapse
|
3
|
Dogan AB, Rohner NA, Smith JNP, Kilgore JA, Williams NS, Markowitz SD, von Recum HA, Desai AB. Polymer Microparticles Prolong Delivery of the 15-PGDH Inhibitor SW033291. Pharmaceutics 2021; 14:85. [PMID: 35056981 PMCID: PMC8779392 DOI: 10.3390/pharmaceutics14010085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Revised: 12/06/2021] [Accepted: 12/21/2021] [Indexed: 11/16/2022] Open
Abstract
As the prevalence of age-related fibrotic diseases continues to increase, novel antifibrotic therapies are emerging to address clinical needs. However, many novel therapeutics for managing chronic fibrosis are small-molecule drugs that require frequent dosing to attain effective concentrations. Although bolus parenteral administrations have become standard clinical practice, an extended delivery platform would achieve steady-state concentrations over a longer time period with fewer administrations. This study lays the foundation for the development of a sustained release platform for the delivery of (+)SW033291, a potent, small-molecule inhibitor of the 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme, which has previously demonstrated efficacy in a murine model of pulmonary fibrosis. Herein, we leverage fine-tuned cyclodextrin microparticles-specifically, β-CD microparticles (β-CD MPs)-to extend the delivery of the 15-PGDH inhibitor, (+)SW033291, to over one week.
Collapse
Affiliation(s)
- Alan B. Dogan
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, USA; (A.B.D.); (N.A.R.); (H.A.v.R.)
| | - Nathan A. Rohner
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, USA; (A.B.D.); (N.A.R.); (H.A.v.R.)
| | - Julianne N. P. Smith
- Department of Medicine and Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA; (J.N.P.S.); (S.D.M.)
| | - Jessica A. Kilgore
- Department of Biochemistry, UT Southwestern Medical Center, Dallas, TX 75390, USA; (J.A.K.); (N.S.W.)
| | - Noelle S. Williams
- Department of Biochemistry, UT Southwestern Medical Center, Dallas, TX 75390, USA; (J.A.K.); (N.S.W.)
| | - Sanford D. Markowitz
- Department of Medicine and Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA; (J.N.P.S.); (S.D.M.)
- University Hospitals Seidman Cancer Center, Cleveland, OH 44106, USA
| | - Horst A. von Recum
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, USA; (A.B.D.); (N.A.R.); (H.A.v.R.)
| | - Amar B. Desai
- Department of Medicine and Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA; (J.N.P.S.); (S.D.M.)
| |
Collapse
|
4
|
Affinity-Based Polymers Provide Long-Term Immunotherapeutic Drug Delivery Across Particle Size Ranges Optimal for Macrophage Targeting. J Pharm Sci 2020; 110:1693-1700. [PMID: 33127427 DOI: 10.1016/j.xphs.2020.10.046] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Revised: 09/19/2020] [Accepted: 10/23/2020] [Indexed: 11/23/2022]
Abstract
Drug delivery to specific arms of the immune system can be technically challenging to provide prolonged drug release while limiting off-target toxicity given the limitations of current drug delivery systems. In this work, we test the design of a cyclodextrin (CD) polymer platform to extend immunomodulatory drug delivery via affinity interactions for sustained release at multiple size scales. The parameter space of synthesis variables influencing particle nucleation and growth (pre-incubation time and stirring speed) and post-synthesis grinding effects on resulting particle diameter were characterized. We demonstrate that polymerized CD forms exhibit size-independent release profiles of the small molecule drug lenalidomide (LND) and can provide improved drug delivery profiles versus macro-scale CD polymer disks in part due to increased loading efficiency. CD polymer microparticles and smaller, ground particles demonstrated no significant cytotoxicity as compared to the base CD monomer when co-incubated with fibroblasts. Uptake of ground CD particles was significantly higher following incubation with RAW 264.7 macrophages in culture over standard CD microparticles. Thus, the affinity/structure properties afforded by polymerized CD allow particle size to be modified to affect cellular uptake profiles independently of drug release rate for applications in cell-targeted drug delivery.
Collapse
|
5
|
Engineering selective molecular tethers to enhance suboptimal drug properties. Acta Biomater 2020; 115:383-392. [PMID: 32846237 DOI: 10.1016/j.actbio.2020.07.045] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Revised: 07/22/2020] [Accepted: 07/23/2020] [Indexed: 12/28/2022]
Abstract
Small-molecule drugs are utilized in a wide variety of clinical applications, however, many of these drugs suffer from one or more suboptimal properties that can hinder its delivery or cellular action in vivo, or even shelf an otherwise biologically tolerable drug. While high-throughput screening provides a method to discover drugs with altered chemical properties, directly engineering small-molecule bioconjugates provides an opportunity to specifically modulate drug properties rather than sifting through large drug libraries with seemingly 'random' drug properties. Herein, we propose that selectively "tethering" a drug molecule to an additional group with favorable properties will improve the drug conjugate's overall properties, such as solubility. Specifically, we outlined the site-specific chemical conjugation of rapamycin (RAP) to an additional "high-affinity" group to increase the overall affinity the drug has for cyclodextrin-based polymers (pCD). By doing so, we found that RAP's affinity for pCD and RAP's window of delivery from pCD microparticles was tripled without sacrificing RAP's cellular action. This synthesis method was applied to the concept of "affinity" for pCD, but other prosthetic groups can be used similarly. This study displays potential for increasing drug delivery windows of small-molecule drugs in pCD systems for chronic drug therapies and introduces the idea of altering drug properties to tune polymer-drug interactions.
Collapse
|
6
|
Hsu RS, Fang JH, Shen WT, Sheu YC, Su CK, Chiang WH, Hu SH. Injectable DNA-architected nanoraspberry depot-mediated on-demand programmable refilling and release drug delivery. NANOSCALE 2020; 12:11153-11164. [PMID: 32400827 DOI: 10.1039/d0nr01185a] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Drug delivery depots boosting a local concentration of therapeutic agents have received great attention in clinical applications due to their low occurrence of side effects and high therapeutic efficacy. However, once the payload is exhausted, the local drug concentration will be lower than the therapeutic window. To address this issue, an injectable double-strand deoxyribonucleic acid (DNA)-architected nanoraspberry depot (DNR-depot) was developed that can refill doxorubicin (Dox, an anticancer drug) from the blood and remotely control drug release on demand. The large porous surface on a uniform nanoraspberry (NR) filled covalently with DNA serves as a Dox sponge-like refilling reservoir, and the NR serves as a magnetic electrical absorber. Via the strong affinity between Dox and DNA molecules, the refilling process of Dox can be achieved on DNR-depot both in vitro and in vivo. Upon high-frequency magnetic field (HFMF) treatment, the remotely triggered release of Dox is actuated by the dissociation of Dox and DNA molecules, facilitating an approximately 800% improvement in drug concentration at the tumor site compared to free Dox injection alone. Furthermore, the cycles of refilling and release can be carried out more than 3 times in vivo within 21 days. The combination of refilling and HFMF-programmable Dox release in tumors via DNR-depot can effectively inhibit tumor growth for 30 days.
Collapse
Affiliation(s)
- Ru-Siou Hsu
- Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, 300, Taiwan.
| | - Jen-Hung Fang
- Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, 300, Taiwan.
| | - Wei-Ting Shen
- Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, 300, Taiwan.
| | - Yu-Chen Sheu
- Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, 300, Taiwan.
| | - Cheng-Kuan Su
- Department of Chemistry, National Chung Hsing University, Taichung 402, Taiwan
| | - Wen-Hsuan Chiang
- Department of Chemical Engineering, National Chung Hsing University, Taichung 402, Taiwan
| | - Shang-Hsiu Hu
- Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu, 300, Taiwan.
| |
Collapse
|
7
|
Haley RM, Zuckerman ST, Dakhlallah H, Capadona JR, von Recum HA, Ereifej ES. Resveratrol Delivery from Implanted Cyclodextrin Polymers Provides Sustained Antioxidant Effect on Implanted Neural Probes. Int J Mol Sci 2020; 21:ijms21103579. [PMID: 32438593 PMCID: PMC7279014 DOI: 10.3390/ijms21103579] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Revised: 05/08/2020] [Accepted: 05/15/2020] [Indexed: 12/12/2022] Open
Abstract
Intracortical microelectrodes are valuable tools used to study and treat neurological diseases. Due in large part to the oxidative stress and inflammatory response occurring after electrode implantation, the signal quality of these electrodes decreases over time. To alleviate this response, resveratrol, a natural antioxidant which elicits neuroprotective effects through reduction of oxidative stress, was utilized. This work compares traditional systemic delivery of resveratrol to the novel cyclodextrin polymer (pCD) local delivery approach presented herein, both in vitro and in vivo. The pCD displayed an extended resveratrol release for 100 days, as well as 60 days of free radical scavenging activity in vitro. In vivo results indicated that our pCD delivery system successfully delivered resveratrol to the brain with a sustained release for the entire short-duration study (up to 7 days). Interestingly, significantly greater concentrations of resveratrol metabolites were found at the intracortical probe implantation site compared to the systemic administration of resveratrol. Together, our pilot results provide support for the possibility of improving the delivery of resveratrol in an attempt to stabilize long-term neural interfacing applications.
Collapse
Affiliation(s)
- Rebecca M. Haley
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, USA; (R.M.H.); (J.R.C.)
| | - Sean T. Zuckerman
- Affinity Therapeutics, LLC, 11000 Cedar Avenue, Suite 285, Cleveland, OH 44106, USA;
| | - Hassan Dakhlallah
- Veteran Affairs Ann Arbor Healthcare System, Ann Arbor, MI 48105, USA;
| | - Jeffery R. Capadona
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, USA; (R.M.H.); (J.R.C.)
- Advanced Platform Technology Center, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH 44106, USA
| | - Horst A. von Recum
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, USA; (R.M.H.); (J.R.C.)
- Advanced Platform Technology Center, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH 44106, USA
- Correspondence: (H.A.v.R.); (E.S.E.)
| | - Evon S. Ereifej
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, USA; (R.M.H.); (J.R.C.)
- Veteran Affairs Ann Arbor Healthcare System, Ann Arbor, MI 48105, USA;
- Advanced Platform Technology Center, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH 44106, USA
- Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA
- Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA
- Correspondence: (H.A.v.R.); (E.S.E.)
| |
Collapse
|
8
|
Rohner NA, Nguyen D, von Recum HA. Affinity Effects on the Release of Non-Conventional Antifibrotics from Polymer Depots. Pharmaceutics 2020; 12:E275. [PMID: 32192207 PMCID: PMC7151100 DOI: 10.3390/pharmaceutics12030275] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Revised: 03/09/2020] [Accepted: 03/11/2020] [Indexed: 12/02/2022] Open
Abstract
For many chronic fibrotic conditions, there is a need for local, sustained antifibrotic drug delivery. A recent trend in the pharmaceutical industry is the repurposing of approved drugs. This paper investigates drugs that are classically used for anthelmintic activity (pyrvinium pamoate (PYR)), inhibition of adrenal steroidgenesis (metyrapone (MTP)), bactericidal effect (rifampicin (RIF), and treating iron/aluminum toxicity (deferoxamine mesylate (DFOA)), but are also under investigation for their potential positive effect in wound healing. In this role, they have not previously been tested in a localized delivery system suitable for obtaining the release for the weeks-to-months timecourse needed for wound resolution. Herein, two cyclodextrin-based polymer systems, disks and microparticles, are demonstrated to provide the long-term release of all four tested non-conventional wound-healing drugs for up to 30 days. Higher drug affinity binding, as determined from PyRx binding simulations and surface plasmon resonance in vitro, corresponded with extended release amounts, while drug molecular weight and solubility correlated with the improved drug loading efficiency of cyclodextrin polymers. These results, combined, demonstrate that leveraging affinity interactions, in combination with drug choice, can extend the sustained release of drugs with an alternative, complimentary action to resolve wound-healing and reduce fibrotic processes.
Collapse
Affiliation(s)
- Nathan A. Rohner
- Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106, USA;
| | - Dung Nguyen
- Department of Macromolecular Science and Engineering, Case Western Reserve University, 2100 Adelbert Road, Cleveland, OH 44106, USA;
| | - Horst A. von Recum
- Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106, USA;
| |
Collapse
|
9
|
McNamara SL, Brudno Y, Miller AB, Ham HO, Aizenberg M, Chaikof EL, Mooney DJ. Regenerating Antithrombotic Surfaces through Nucleic Acid Displacement. ACS Biomater Sci Eng 2020; 6:2159-2166. [PMID: 33455325 DOI: 10.1021/acsbiomaterials.0c00038] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Blood-contacting devices are commonly coated with antithrombotic agents to prevent clot formation and to extend the lifespan of the device. However, in vivo degradation of these bioactive surface agents ultimately limits device efficacy and longevity. Here, a regenerative antithrombotic catheter surface treatment is developed using oligodeoxynucleotide (ODN) toehold exchange. ODN strands modified to carry antithrombotic payloads can inhibit the thrombin enzyme when bound to a surface and exchange with rapid kinetics over multiple cycles, even while carrying large payloads. The surface-bound ODNs inhibit thrombin activity to significantly reduce fibrinogen cleavage and fibrin formation, and this effect is sustained after ODN exchange of the surface-bound strands with a fresh antithrombotic payload. This study presents a unique strategy for achieving a continuous antithrombotic state for blood-contacting devices using an ODN-based regeneration method.
Collapse
Affiliation(s)
- Stephanie L McNamara
- John A. Paulson School of Engineering and Applied Sciences, Harvard University, 29 Oxford Street, Cambridge, Massachusetts 02138, United States.,Harvard-MIT Health Sciences and Technology, Harvard University and Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02138, United States.,Wyss Institute for Biologically Inspired Engineering, 3 Blackfan Circle, Boston, Massachusetts 02215, United States
| | - Yevgeny Brudno
- Joint Department of Biomedical Engineering, University of North Carolina and North Carolina State University, 911 Oval Drive, Raleigh, North Carolina 27695, United States.,Wyss Institute for Biologically Inspired Engineering, 3 Blackfan Circle, Boston, Massachusetts 02215, United States
| | - Alex B Miller
- Harvard-MIT Health Sciences and Technology, Harvard University and Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02138, United States
| | - Hyun Oki Ham
- Wyss Institute for Biologically Inspired Engineering, 3 Blackfan Circle, Boston, Massachusetts 02215, United States.,Department of Surgery, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215, United States
| | - Michael Aizenberg
- Wyss Institute for Biologically Inspired Engineering, 3 Blackfan Circle, Boston, Massachusetts 02215, United States
| | - Elliot L Chaikof
- Harvard-MIT Health Sciences and Technology, Harvard University and Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02138, United States.,Wyss Institute for Biologically Inspired Engineering, 3 Blackfan Circle, Boston, Massachusetts 02215, United States.,Department of Surgery, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215, United States
| | - David J Mooney
- John A. Paulson School of Engineering and Applied Sciences, Harvard University, 29 Oxford Street, Cambridge, Massachusetts 02138, United States.,Wyss Institute for Biologically Inspired Engineering, 3 Blackfan Circle, Boston, Massachusetts 02215, United States
| |
Collapse
|